Literature DB >> 22503967

Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist.

Mark G LeSage1, David Shelley, Marco Pravetoni, Paul R Pentel.   

Abstract

Tobacco addiction requires activation by nicotine of a variety of central nicotinic acetylcholine receptors (nAChRs). In animals, both nAChR antagonists and immunization against nicotine can reduce nAChR activation by nicotine and block a variety of addiction-relevant behaviors. However, clinical use of nAChR antagonists for smoking cessation is limited by dose-related side effects, and immunization does not reliably produce sufficient antibody levels in smokers to enhance smoking cessation rates. Combining these approaches may be one way of addressing the limitations of each while enhancing overall efficacy. This study examined the individual and combined effects of passive immunization with the monoclonal nicotine-specific antibody Nic311 and the nicotinic receptor antagonist mecamylamine (MEC) on nicotine's discriminative stimulus effects. Rats were trained to discriminate 0.4 mg/kg of nicotine from saline using a two-lever operant discrimination procedure. Antagonism of nicotine discrimination by Nic311 (160 mg/kg i.v.) and ascending doses of MEC (0.03, 0.1, 0.3, and 1.0 mg/kg s.c.) was assessed across four consecutive daily 2-min extinction test sessions using a 2×2 design. Nic311 alone produced a 24-48% reduction in % nicotine-lever responding (%NLR) across all four test sessions. MEC produced a dose-dependent decrease in %NLR, with no effect at the two lowest doses and 80-93% attenuation at the two highest doses. Nic311 combined with MEC significantly suppressed %NLR at every MEC dose (85-92% reduction across all four test sessions). Very low doses of MEC that were ineffective alone completely blocked nicotine discrimination when combined with Nic311. These data demonstrate that nicotine-specific antibodies and MEC can work synergistically to suppress the subjective effects of nicotine and suggest that low doses of MEC may significantly enhance the efficacy of immunotherapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503967      PMCID: PMC3357089          DOI: 10.1016/j.pbb.2012.03.026

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  44 in total

1.  Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations.

Authors:  Mark G LeSage; Daniel E Keyler; Greg Collins; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

2.  Passive immunization against nicotine attenuates nicotine discrimination.

Authors:  David H Malin; Candice L Alvarado; Katherine S Woodhouse; Hilary Karp; Evelyn Urdiales; Diana Lay; Phillip Appleby; William D Moon; Sofiane Ennifar; Lisa Basham; Ali Fattom
Journal:  Life Sci       Date:  2002-04-26       Impact factor: 5.037

3.  Studies on the time course and the effect of cholinergic and adrenergic receptor blockers on the stimulus effect of nicotine.

Authors:  I D Hirschhorn; J A Rosecrans
Journal:  Psychopharmacologia       Date:  1974

4.  Nicotine and bupropion share a similar discriminative stimulus effect.

Authors:  Richard Young; Richard A Glennon
Journal:  Eur J Pharmacol       Date:  2002-05-17       Impact factor: 4.432

5.  Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine.

Authors:  R S Mansbach; L K Chambers; C C Rovetti
Journal:  Psychopharmacology (Berl)       Date:  2000-02       Impact factor: 4.530

6.  N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices.

Authors:  Lincoln H Wilkins; Aaron Haubner; Joshua T Ayers; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

7.  Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant.

Authors:  Sam D Sanderson; Srinivasa R Cheruku; Maniyan P Padmanilayam; Jonathan L Vennerstrom; Geoffrey M Thiele; Matthew I Palmatier; Rick A Bevins
Journal:  Int Immunopharmacol       Date:  2003-01       Impact factor: 4.932

8.  Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats.

Authors:  N Lindblom; S H L de Villiers; G Kalayanov; S Gordon; A M Johansson; T H Svensson
Journal:  Respiration       Date:  2002       Impact factor: 3.580

9.  Role of training dose in discrimination of nicotine and related compounds by rats.

Authors:  I P Stolerman; H S Garcha; J A Pratt; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat.

Authors:  Neil E Paterson; Wolfgang Froestl; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-11-11       Impact factor: 4.530

View more
  9 in total

Review 1.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

2.  Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

3.  Restraint stress attenuates nicotine's locomotor stimulant but not discriminative stimulus effects in rats.

Authors:  Andrew C Harris; Christina Mattson; David Shelley; Mark G LeSage
Journal:  Pharmacol Biochem Behav       Date:  2014-05-24       Impact factor: 3.533

Review 4.  New directions in nicotine vaccine design and use.

Authors:  Paul R Pentel; Mark G LeSage
Journal:  Adv Pharmacol       Date:  2014

5.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

6.  Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats.

Authors:  M G LeSage; M Staley; P Muelken; J R Smethells; I Stepanov; R I Vogel; P R Pentel; A C Harris
Journal:  Drug Alcohol Depend       Date:  2016-09-01       Impact factor: 4.492

7.  Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions.

Authors:  Katherine E Cornish; Sabina H L de Villiers; Marco Pravetoni; Paul R Pentel
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 8.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

9.  The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats.

Authors:  Paul R Pentel; Michael D Raleigh; Mark G LeSage; Thomas Thisted; Stephen Horrigan; Zuzana Biesova; Matthew W Kalnik
Journal:  BMC Biotechnol       Date:  2018-07-24       Impact factor: 2.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.